CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...